Jingwei Wu

Title: Innovations of Inventor Jingwei Wu in Pharmaceutical Research

Introduction

Jingwei Wu, a distinguished inventor based in Tianjin, China, has made significant contributions to the field of pharmaceutical research. With a total of three patents, his innovative work focuses on enhancing the effectiveness and stability of pharmaceutical compounds.

Latest Patents

Jingwei Wu's latest inventions include the development of a crystal form of urate transporter 1 inhibitor along with its preparation method and use. This crystal form is notable for its stable appearance, improved purity, and enhanced storage stability, making it an ideal pharmaceutical raw material. Additionally, he has created a method for preparing a URAT1 inhibitor, specifically 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid, which boasts benefits such as low cost, ease of handling, and applicability to industrialization, thus representing a notable advancement over prior art.

Career Highlights

Wu's career is marked by his position at the Tianjin Institute of Pharmaceutical Research Co., Ltd. Here, he continues to push the boundaries of pharmaceutical innovation, working diligently to develop new and effective treatment options.

Collaborations

In his endeavors, Wu collaborates with notable colleagues including Guilong Zhao and Changying Liu. Their combined expertise in the research field fosters a dynamic environment for innovative discoveries and developments.

Conclusion

With his groundbreaking patents and collaborative efforts at the Tianjin Institute of Pharmaceutical Research, Jingwei Wu exemplifies the spirit of innovation in the pharmaceutical industry. His work not only advances the field but also holds the promise of delivering better therapeutic options for patients globally.